Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04609514 · ClinicalTrials.gov registry record · NA
Learn to Quit-HIV Pilot Study
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 51
- Enrollment target
NCT04609514: Completed NA study, sponsored by Duke University.
NCT04609514 is a NA study that has completed, run by Duke University. The registered enrollment target is 51 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04609514, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 51 participants
- Enrollment target
Study Summary
The study team will conduct a feasibility, acceptability, and preliminary efficacy trial comparing Learn to Quit-HIV (n=30) to an app based on U.S. Clinical Practice Guidelines only (NCI QuitGuide; n=30) among HIV-positive smokers. Both apps will be integrated with NRT and ongoing HIV clinical care.
Primary Outcome
Average duration of app use per arm over participants' 3 months of study participation
Interventions
- DRUG Nicotine patch
- BEHAVIORAL QuitGuide
- DEVICE Learn to Quit-HIV
- BEHAVIORAL Smartphone coaching
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2021-01-25 |
| Est. Completion | 2022-06-02 |
| Phase | NA |
What the finished NCT04609514 record still lists
NCT04609514 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 4 interventions - of which Nicotine patch is the first listed.
NCT04609514 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04609514 about?
NCT04609514 is a clinical study titled "Learn to Quit-HIV Pilot Study". The study team will conduct a feasibility, acceptability, and preliminary efficacy trial comparing Learn to Quit-HIV (n=30) to an app based on U.S. Clinical Practice Guidelines only (NCI QuitGuide; n=30) among HIV-positive smokers. Both apps will be integrated with NRT and ongoing HIV clinical care.
What is the current status of trial NCT04609514?
This trial is currently completed. It is a NA study. The enrollment target is 51 participants. The study started on 2021-01-25. Estimated completion is 2022-06-02.
What interventions are being tested in trial NCT04609514?
The interventions under investigation include: Nicotine patch (DRUG), QuitGuide (BEHAVIORAL), Learn to Quit-HIV (DEVICE), Smartphone coaching (BEHAVIORAL).
Who is sponsoring clinical trial NCT04609514?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04609514's enrollment target sits among peer trials
51 1279th of 2000 higher than 722 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI